Why the study?
Does Cop 1 reduce the clinical incidence of experimental allergic encephalomyelitis in an animal model?
Does Cop 1 reduce the clinical incidence of experimental allergic encephalomyelitis in an animal model?
Answers are grounded in this paper and cite their sources.
The synthetic polypeptide Cop 1 significantly suppresses the clinical incidence and histological severity of experimental allergic encephalomyelitis.
Three random basic copolymers of amino acids were tested for their effect on experimental allergic encephalomyelitis (EAE). One of these copolymers denoted as Cop 1, composed of alanine, glutamic acid, lysine and tyrosine, with a molecular weight of 23 000, showed a marked suppressive effect on the disease. The intravenous administration of Cop 1 in physiological saline, as late as 5 days following the challenge with the disease‐inducing dose of the basic encephalitogenic protein, reduced the clinical incidence of EAE from 64% in the control group to 22%; the histological lesions were also decreased both in prevalence and in severity. The suppressive effect on the disease attained by the synthetic copolymer is of the same order of magnitude as that previously reported for the basic encephalitogen. The effect of the copolymers appears to be specific, since neither an acidic amino acid copolymer, nor unrelated basic proteins, had any protective action. On the other hand, a second batch of Cop 1 showed activity identical to that of the first batch. The potential applicability of this non‐encephalitogenic and non‐immunosuppressive material is discussed.
No takes yet. Share an insight, caveat, or question.
Teitelbaum et al. (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: